A therosclerotic cardiovascular disease (ACVD) affects > 82 million people in the United States. Lipid-lowering therapy is the major current strategy in managing ACVD and has reduced cardiovascular events by about 30 to 50%, leaving a substantial percentage of patients who continue to suffer ischemic events. Inflammation and immune system activation has been implicated in the pathophysiology of athero-thrombosis. The CANTOS trial (The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) provided the first clinical evidence demonstrating the efficacy of targeting inflammation in reducing cardiovascular events. Modulation of the immune system is another potentially attractive option for management of ACVD.
Clean water and vaccines against many infectious diseases have been major public health advances in the past 100 years. In modern times, ACVD is the leading cause of death in most countries. Atherosclerosis is a complex process involving lipid deposition and activation of immune and inflammatory responses which ultimately result in cardiovascular events through acute and chronic arterial luminal compromise. Currently, risk factor modification, including lipid-modifying therapy, is the major strategy in managing ACVD. Although clinical trials of low-density lipoprotein cholesterol (LDL-C) lowering agents (Statins, Ezetimibe, PCSK9 [proprotein convertase subtilisin/kexin 9] inhibitors) have generally achieved reduction in cardiovascular events, a substantial percentage of patients continue to experience ischemic events, despite such therapies.
A large body of evidence has implicated immune activation and inflammation in mediating atherosclerotic cardiovascular events, and the CANTOS trial provided the first clinical evidence that targeting 1 potential pathway of inflammation directly may also reduce cardiovascular events.
1 The clinical benefits in CANTOS trial in which an IL-1β (interleukin 1β) antibody was used were rather modest and counterbalanced by increased risk of fatal infections. In addition, widespread use of anti-inflammatory cytokine therapy, such as Canakinumab in the CANTOS trial will be limited because of high cost, need for frequent administration, relatively short duration of therapeutic action, and nonspecific suppression of inflammatory response leading to increased incidence of fatal infection.
1 Other approaches to quell arterial inflammation deserve pursuit.
Vaccination Against Atherosclerosis
Existence of both proatherogenic and athero-protective immune responses have led to the notion that suppressing proatherogenic immune response or activation of an atheroprotective immune response may be beneficial in atherosclerosis. These pathophysiologic principles hence raise the tantalizing possibility that immune-modulation using a vaccine or specific antibody could favorably alter the natural history of atherosclerosis. Modification of the immune response using a vaccine containing antigen(s) relevant to atherogenesis may provide a specific immune response against relevant antigens without affecting global immunity and with the potential for a more sustained and long-term effect.
Gero et al 2 showed the potential feasibility of this approach in experimental atherosclerosis using lipid antigens in 1959. In the late 1980s, T cells reactive to LDL were observed in human atherosclerotic plaques, and humoral immunity against LDL could be detected in patients with ACVD. 3 These observations, together with the epidemiological and causal link between LDL and atherosclerosis, led to a renewed interest to test if immunemodulation by immunization against LDL was atherogenic or athero-protective. Since then we and others have reported antiatherogenic effects of immunization with LDL (native or modified) in hypercholesterolemic animals. 4 Further refinements in this approach were reported from our laboratory and that of our collaborator, Jan Nilsson, using peptide antigens which we identified in human apoB-100 that reduced atherosclerosis in various murine models defining a potential clinically usable pathway for vaccination against atherosclerosis, angiotensininduced hypertension, or aortic aneurysm. [4] [5] [6] Other investigators have recently confirmed the benefits of apoB-100 related peptide immunization in murine atherosclerosis. 7 Although the precise mechanism(s) by which these peptide vaccines produce favorable results in animal models are incompletely understood, humoral antibody response, Treg activation, suppression of CD4+T-cell response, and modulation of dendritic cells and CD8+T-cell response have all been implicated. 4 We think that apoB-100 related peptides vaccines are logical choices for initial testing because numerous clinical trials have established the causative role of LDL in atherogenesis, and preclinical studies using LDL or selected apoB-100 peptides as candidate antigens reduce experimental atherosclerosis. Based on current observations from preclinical studies, the premise for vaccination to reduce atherosclerosis is based on the existence of immune responses against LDL or apoB-100
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October 26, 2018 related peptide antigens in vivo and ability of immunization with these antigens to modulate such responses by affecting cellular immune responses mediated by various subsets of T cells. 4 This suggests that for vaccination strategy to succeed in reducing atherosclerosis, an autoimmune response to the autoantigen needs to be present. Hence, whether a vaccination strategy would have the potential to work in human subjects could depend on whether an autoimmune response is present to that particular antigen in human subjects. Humoral immune responses to endogenous apoB-100 related peptide antigens do exist in humans suggesting that immunization with such apoB-100 related peptide antigens could modulate atherosclerosis. 8 This expectation obviously requires scientific validation.
Clinical testing of apoB-100 related peptide vaccines is likely soon as formulation of the vaccine product is optimized for human testing with appropriate carrier/adjuvant components. Further improvements in vaccine formulation, using nanotechnology platform, has the potential to induce an athero-protective antigen-specific Treg response suppressing an adverse autoimmune response in atherosclerosis. 9 Passive immunization using an antibody against apoB-100 peptide p45, as reported by our group, offers another approach to immune-modulation of atherosclerosis. 10 A recent murine study indicates that LDL-reactive T cells can elicit humoral immunity to LDL to promote LDL clearance and reduce atherosclerosis by triggering B-cell activation, germinal center formation, and production of high-affinity antibodies to LDL. 11 Such an antibody(ies), may be useful for short-term use as an adjuvant to lipid-lowering therapy to rapidly clear cholesterol from tissue or circulation.
Other Potential Vaccination Strategies
Recently passive immunization with monoclonal antibodies to secreted PCSK9 have been approved for clinical use to reduce circulating LDL-C and cardiovascular events. A vaccine against PCSK9 to lower LDL-C has shown promising results in animal models and is likely to rapidly move into clinical testing phase. 12, 13 Many additional antigens were also reported to confer athero-protection when tested in vaccine formulation (Table) . However, given the complex nature of atherosclerosis, the list of antigens is likely to be longer. To discover these new antigens from a complex disease, such as atherosclerosis, the experience from infectious disease and oncology will be useful to the scientists. Vaccinology has evolved from using attenuated organisms as immunogen, cell culture of virus, genetic engineering to produce microbial proteins in culture to reverse vaccinology by analyzing genomic information to identify genes coding protective proteins.
14 A systematic analysis of atherosclerosis immunogenomics, a concept similar to cancer immunogenomics, 15 will enable the researchers to identify more atherosclerosis-specific alteration of antigenic epitopes that can elicit a protective immune response.
Validating the Clinical Benefits of Vaccination
At present, we think that quantitative computed tomography coronary angiography may be suitable for measuring changes in calcified and noncalcified plaque burden in response to therapeutic intervention to provide a rapid proof of concept regarding efficacy before the more expensive and long-term outcomes-based trials are launched. In the meantime, monitoring immune parameters, such as antigen-specific humoral or cellular immune responses would be useful in clinical trials if such immune responses can be linked to favorable outcomes or adverse effects.
Conclusions
Lipids, inflammation, and immune response are tightly linked in the development of atherosclerosis and clinical ACVD. Breaking this triangular relationship by targeting any one of the angles could lead to beneficial clinical effect. Two of the 3 components already have established clinical evidence for efficacy. The idea of developing vaccination strategies to modulate the highly prevalent ACVD is exciting but still in its infancy. Many challenging questions, such as vaccine formulation, route of delivery, schedule and durability of vaccination, proper patient selection for testing, and monitoring of efficacy endpoints or safety issues remain to be answered in ongoing preclinical and clinical testing. However, despite many challenges, we think that active as well as passive immune-modulation using apoB-100 related antigen(s) has the potential to transform cardiovascular prevention. 
